During that meeting, PacBio launched not one, but two, new sequencing instruments. First, the short-read instrument “Onso,” sparked by their acquisition of Omniome’s short-read, sequencing ...

Shares of 10x Genomics and Illumina are down some 40% this year. Sales of their research equipment have been hurt by ...

With Illumina currently banned from shipping its DNA sequencers into China—in retaliation for the Trump administration’s ...

In August, PacBio announced the commencement of customer shipments of Onso short-read sequencing instruments. In April, PacBio announced the availability of its new high-throughput Nanobind DNA ...

Going forward, PacBio said it will “focus on its highest-impact long-read platform development initiatives” via its HiFi sequencing instruments, including the Vega benchtop analyzer announced ...

Goldman Sachs downgraded its recommendation on PacBio (NASDAQ ... academic funding have clouded the investment outlook for new instruments. He added that compared to its rival Agilent (A), PacBio ...

PacBio’s earnings surpassed the Zacks Consensus ... enabling it to deliver instruments based on demand much more rapidly. This strengthened its ability to sell the system. Per management ...